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Patrick T Ellinor,4,5 David D McManus,6 Darae Ko,7 Lu-Chen Weng,4,5 Kathryn L Lunetta,1,3 
Lars Frost,8 Emelia J Benjamin,1,7,9 Ludovic Trinquart3
ABSTRACT
OBJECTIVE
To examine the association between risk factor 
burdens—categorized as optimal, borderline, or 
elevated—and the lifetime risk of atrial fibrillation.
DESIGN
Community based cohort study.
SETTING
Longitudinal data from the Framingham Heart Study.
PARTICIPANTS
Individuals free of atrial fibrillation at index ages 55, 
65, and 75 years were assessed. Smoking, alcohol 
consumption, body mass index, blood pressure, 
diabetes, and history of heart failure or myocardial 
infarction were assessed as being optimal (that is, 
all risk factors were optimal), borderline (presence of 
borderline risk factors and absence of any elevated 
risk factor), or elevated (presence of at least one 
elevated risk factor) at index age.
MAIN OUTCOME MEASURE
Lifetime risk of atrial fibrillation at index age up to 95 
years, accounting for the competing risk of death.
RESULTS
At index age 55 years, the study sample comprised 
5338 participants (2531 (47.4%) men). In this group, 
247 (4.6%) had an optimal risk profile, 1415 (26.5%) 
had a borderline risk profile, and 3676 (68.9%) an 
elevated risk profile. The prevalence of elevated risk 
factors increased gradually when the index ages 
rose. For index age of 55 years, the lifetime risk of 
atrial fibrillation was 37.0% (95% confidence interval 
34.3% to 39.6%). The lifetime risk of atrial fibrillation 
was 23.4% (12.8% to 34.5%) with an optimal risk 
profile, 33.4% (27.9% to 38.9%) with a borderline 
risk profile, and 38.4% (35.5% to 41.4%) with an 
elevated risk profile. Overall, participants with at least 
one elevated risk factor were associated with at least 
37.8% lifetime risk of atrial fibrillation. The gradient 
in lifetime risk across risk factor burden was similar at 
index ages 65 and 75 years.
CONCLUSIONS
Regardless of index ages at 55, 65, or 75 years, an 
optimal risk factor profile was associated with a 
lifetime risk of atrial fibrillation of about one in five; 
this risk rose to more than one in three in individuals 
with at least one elevated risk factor.
Introduction
Advancing age is a prominent risk factor of atrial 
fibrillation.1 Ongoing improvements of health and 
medicine, such as public health efforts, m edical 
treatments, and surgical interventions, have delayed 
senescence and postponed mortality.2 This extended 
longevity has increased the risk of age related diseases 
such as atrial fibrillation.2 Worldwide, a rapid upward 
trajectory of prevalence and incidence of atrial 
fibrillation is occurring,3 and in the United States, 
the number of individuals with atrial fibrillation has 
been projected to rise to about 12 to 15 million by 
2050.4 5 Preventive strategies for atrial fibrillation are 
therefore highly important, owing to estimated death 
rates of 20% and 50% at one and five years after initial 
diagnosis in older adults, respectively.6
In addition to advancing age, several short term 
risk factors for incident atrial fibrillation have been 
identified. Established risk factors for developing atrial 
fibrillation within 10 years include cigarette smoking, 
alcohol misuse, hypertension, obesity, diabetes, 
myocardial infarction, and heart failure.1 7-9 Modifiable 
risk factors could be associated with increased risk 
of atrial fibrillation even if they were previously 
considered borderline—for example, systolic blood 
pressure of 130-139 mm Hg and overweight (body 
mass index 25-30).10 The elevation of one risk factor 
rarely occurs in isolation, because many people often 
have a mixture of borderline or elevated levels of risk 
factors.7 9-11 The prevalence of multimorbidity (defined 
as two or more chronic morbidities) is about 23%, and 
the proportion of individuals with multimorbidities 
increases with advancing age.11 The accumulation of 
risk factors imposes an additive risk for developing 
atrial fibrillation.8 9
Predictive risk scores have examined the risk of atrial 
fibrillation within timeframes of fi ve or 10 years.8  9 
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WhAT IS AlReAdy knoWn on ThIS TopIC
The lifetime risk of atrial fibrillation has been estimated to be about one in four 
at age 40 years or above
Short term clinical risk factors for atrial fibrillation are well established, but how 
the risk factor burden affects the lifetime risk of atrial fibrillation is not known
WhAT ThIS STudy AddS
The overall lifetime risk of atrial fibrillation was 37.0% among individuals aged 
55 years or older; lifetime risk was higher among men than women
Individuals with an optimal risk factor profile at 55 years had a lifetime risk of 
atrial fibrillation of about one in five, whereas those with elevated risk factors 
had a lifetime risk of at least one in three
Preventive efforts to reduce the disease burden should target modifiable 
borderline and elevated risk factors plus consider multimorbidity
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Lifetime risk has proved to be a useful quantification 
of the absolute risk over a person’s lifetime, and is an 
essential addition to the use of short term relative risks 
in clinical practice. The lifetime risk of atrial fibrillation 
has been reported to range from 17% to 26% in men 
and from 21% to 23% in women aged 40 years or 
older.12-15 However, data are scarce with respect to 
the lifetime risk of atrial fibrillation in the presence 
of one or multiple risk factors. Moreover, knowledge 
is limited about the lifetime risk of atrial fibrillation 
with borderline-elevated risk factors; predictive risk 
scores primarily focus on elevated risk factors without 
accounting for borderline-elevated risk factors.8 9
By contrast with the relative risk of atrial fibrillation, 
lifetime risk is an easy way for clinicians to communicate 
future risk of atrial fibrillation to individuals. Estimating 
the lifetime risk of atrial fibrillation in various subgroups 
with one or multiple elevated or borderline-elevated 
risk factors might also help to design preventive 
strategies.11 16 In this community based cohort study, we 
hypothesized that the risk factor burden—categorized as 
optimal, borderline, or elevated—is associated with an 
increased lifetime risk of atrial fibrillation.
Methods
We included participants in the Framingham Heart 
Study who did not have atrial fibrillation at one or more 
index ages of 55, 65, and 75 years. The lifetime risk 
of atrial fibrillation was estimated from the index age 
to 95 years of age, with adjustment for the competing 
risk of death without atrial fibrillation. We considered 
smoking, alcohol consumption, body mass index, 
blood pressure, diabetes, and history of myocardial 
infarction or heart failure at an index age. We then 
defined the risk factor burdens as optimal (that is, 
all risk factors were optimal), elevated (at least one 
risk factor elevated), and borderline (otherwise), and 
compared the lifetime risk estimates according to those 
levels of risk factor burden.
Data source
We used longitudinal data from the Framingham 
Heart Study. In 1948, participants were enrolled in 
the original cohort (n=5209), and they were examined 
every two years with standardized Framingham Heart 
Study examinations comprising a collection of data 
(medical history, physical examination, and laboratory 
tests). In 1971, children of the original cohort and their 
spouses were enrolled in the offspring cohort (n=5124), 
and were examined every four to eight years.17 In 
2002, adult children from the offspring cohort were 
enrolled in the third generation cohort (n=4095), and 
were examined every six to eight years.18
Study samples
Participants from the original cohort’s examination 
cycle 11 to 28 (from year 1968 to 2005), the offspring 
cohort’s examination cycle one to nine (from 1971 to 
2014), and the third generation’s examination cycle 
one or two (from 2002 to 2014) could enter one or 
more of three age study samples, provided that their 
risk factors were available. The three study samples 
were at index age 55 years, index age 65 years, and 
index age 75 years.
Smoking, alcohol consumption, body mass 
index, blood pressure, and diabetes were recorded 
from Framingham Heart Study examinations, and 
history of cardiovascular disease was recorded from 
hospital records. A panel of three medical doctors 
(the Framingham Endpoint Review Committee) 
validated the Framingham Heart Study sequence 
of cardiovascular events, and the review was based 
on medical records and study participant history. 
Cardiovascular disease was considered to have 
developed if there was a definite manifestation of 
coronary heart disease (angina pectoris, coronary 
insufficiency, myocardial infarction), intermittent 
claudication, congestive heart failure, or stroke or 
transient ischemic attack in the absence of a previous 
manifestation of any of these diseases.
The Framingham Heart Study examination or 
hospital record closest to the age benchmark was 
used. At index age 55 years, we selected participants 
according to the following criteria:
•   Excluded  participants  who  developed  atrial 
fibrillation or died before age 55 years
•   Excluded  participants  who  did  not  have  a 
Framingham Heart Study examination, between 
ages 50 and 59 years (that is, <60 years)
•   Included individuals who had covariates measured 
between age 50 and 59 years (that is, <60 years)
•   Excluded participants with atrial fibrillation present 
before the recording of risk factors.
If risk factors were measured between age 50 and 55 
years, the risk time started at 55 years. If risk factors 
were measured between age 55 and 59 years (that 
is, <60 years), the risk time started at the specific age 
when risk factors were measured. We used the same 
approaches to select participants for study samples 
with index ages 65 years (supplementary fig 1) and 75 
years (supplementary fig 2).
Risk factor categories
Risk factors were selected on the basis of the CHARGE-AF 
risk score and literature.1 8 10 19 The risk factors comprised 
smoking, alcohol consumption, body mass index, blood 
pressure, diabetes mellitus (type 1 or 2), and history 
of myocardial infarction or heart failure. We defined 
optimal, borderline, and elevated categories for each 
risk factor (except for alcohol consumption and history 
of heart failure or myocardial infarction) according to a 
previous study,10 as described in table 1.
Presence of multiple borderline or elevated risk 
factors were evaluated according to three levels: 
all risk factors were optimal (optimal), presence of 
borderline risk factors and absence of any elevated risk 
factor (borderline), or presence of elevated risk factors 
(elevated).
Measurement of atrial fibrillation
Atrial fibrillation was diagnosed as either atrial flutter 
or fibrillation. We determined atrial fibrillation by 
RESEARCH
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electrocardiograms from Framingham Heart Study 
examinations, participants’ medical appointments, or 
hospital records. Framingham Heart Study personnel 
contacted hospitals and medical clinics to collect 
the participants’ medical records. Two cardiologists 
evaluated records for newly diagnosed atrial 
fibrillation.
Participants in the three age samples (at ages 55, 
65, and 75 years) were followed from the attained 
age free of atrial fibrillation to the earliest of the 
following dates: first diagnosed atrial fibrillation, 
last Framingham Heart Study visit or medical contact 
in which the participant was known as free of atrial 
fibrillation, age 95 years, death, or end of follow-up 
(31 December 2014).
Statistical analysis
We calculated the lifetime risks for the first incident 
atrial fibrillation from index ages 55, 65, and 75 years 
up to age 95 years. For example, the remaining lifetime 
risk for atrial fibrillation for 55 year old participants 
was the cumulative incidence of atrial fibrillation over 
40 years. The standard Kaplan-Meier estimates do not 
take into account the competing risk of death (meaning 
that participants who die without atrial fibrillation no 
longer are at risk of atrial fibrillation) and overestimate 
absolute risks. Therefore, we used a modified Kaplan-
Meier estimator with age as the time scale, accounting 
for the competing risk of death to compute the lifetime 
cumulative risk of atrial fibrillation and associated 
95% confidence intervals.20
We computed lifetime risk in subgroups of 
participants according to their risk profile at a specified 
index age (optimal, borderline, and elevated), for each 
risk factor separately and for the combination of risk 
factors. Lifetime risk estimates in the elevated and 
borderline risk groups were compared with the lifetime 
risk estimated in the optimal risk group by a z ratio 
test (that is, the difference in lifetime risk between two 
groups divided by its standard error). We also tested 
for an interaction between sex and the risk categories 
in their effect on the subdistribution hazard of atrial 
fibrillation. The analyses were broken down further 
according to the number of borderline or elevated risk 
factors. Moreover, we fitted a multivariable Fine and 
Gray model, adjusted for competing risk of death to 
predict the lifetime risk of atrial fibrillation (details 
shown in the supplementary methods). We checked the 
assumptions of the model.21 The proportional hazards 
assumption was violated for body mass index, sex, 
smoking, and history of myocardial infarction or heart 
failure. Interaction terms were added between each 
covariate and the natural logarithmic transformation 
of time. We present the predicted lifetime risk of atrial 
fibrillation for 16 risk profiles, in men and women 
separately.
In secondary analyses, we estimated unadjusted 
cumulative risks, in which participants who died free 
of atrial fibrillation were censored, for each risk factor 
separately.22 The unadjusted cumulative risks were 
reported to assist in the interpretation of the results 
for smoking. We performed two sensitivity analyses. 
Firstly, to account for the exclusion of participants 
with missing data on risk factors, we compared the 
estimated lifetime risk of atrial fibrillation based 
on complete cases and multiple imputation (details 
Table 1 | Definitions of risk factor categories
Risk factor and category Definition
Smoking
Optimal Never smoker
Borderline Former smoker
Elevated Current smoker
Alcohol
Optimal Men ≤14 units of alcohol a week; women ≤7 units of alcohol a week
Elevated Men >14 units of alcohol a week; women >7 units of alcohol a week
Body mass index
Optimal <25
Borderline 25-29
Elevated ≥30
Blood pressure*
Optimal Systolic blood pressure <120 mm Hg and diastolic blood pressure <80 mm Hg, and no treatment for hypertension
Borderline Systolic blood pressure 120-139 mm Hg or diastolic blood pressure 80-89 mm Hg, and no treatment for hypertension
Elevated Systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, and/or treatment for hypertension
Diabetes mellitus (type 1 or 2)
Optimal Fasting blood glucose <100 mg/dL (if fasting blood glucose was not available, non-fasting blood glucose <140 mg/dL was 
used) and no treatment for diabetes
Borderline Fasting blood glucose 100-125 mg/dL (if fasting blood glucose was not available, non-fasting blood glucose 140-199  
mg/dL was used) and no treatment for diabetes
Elevated Fasting blood glucose ≥126 mg/dL (if fasting blood glucose was not available, non-fasting blood glucose ≥200 mg/dL was 
used) or treatment for diabetes
History of heart failure or myocardial infarction
Optimal No history of heart failure or myocardial infarction
Elevated History of heart failure or myocardial infarction
1 mg/dL=0.06 mmol/L.
*Optimal, borderline, and elevated categories in table correspond to categories of normal, elevated and hypertension stage 1, and hypertension stage 2 from the American College of 
Cardiology/American Heart Association 2017 high blood pressure guidelines, respectively. 
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shown in the supplementary methods). Secondly, 
we re-estimated the lifetime risk after discarding 
participants with a body mass index less than 18.5 
from the optimal risk category for body mass index. 
The two sided level of significance was set at less 
than 5%. Data management and statistical analyses 
were performed by SAS (version 9.4 for Windows, SAS 
Institute) and R.23
Patient involvement
No participants from the Framingham Heart Study were 
involved in setting the research question or the outcome 
measures, nor were they involved in developing plans 
for recruitment, design, or implementation of the study. 
No participants were asked to advise on interpretation 
or writing up of results. We report research findings 
from the Framingham Heart Study on the study 
website and selected research results are disseminated 
to participants as part of mailed newsletters annually.
Results
Study samples at index ages 55, 65, and 75 years
The selection of participants for the study samples with 
index ages 55, 65, and 75 years are shown in figure 1 
and supplementary figures 1 and 2, respectively. 
Final numbers of participants in the three age study 
samples were as follows: index age 55 years had 5338 
participants free of atrial fibrillation and 47% were 
men; index age 65 years had 4805 participants free of 
atrial fibrillation and 44% were men; and index age 75 
years had 3199 participants free of atrial fibrillation and 
40% were men. We report characteristics of the three 
study samples in table 2. The most common elevated 
risk factor among participants was elevated blood 
pressure (38% at age 55 years, 57% at 65 years, and 
70% at 75 years). A gradual increase in the presence 
of elevated blood pressure, diabetes, and history of 
myocardial infarction or heart failure was observed as 
index age increased. As index age increased from 55 
years to 75 years, the composition of individuals with 
smoking as an elevated risk factor changed from 21% 
Participants included from Framingham Heart Study (n=12 927):
  Original cohort (examination cycle 11-28; n=3708)
  O­spring cohort (examination cycle 1-9; n=5124)
  Third generation (examination cycle 1-2; n=4095)
Participants in index age cohort 55 years at risk of atrial brillation from age 55 years
or from index examination (if occurring between age 55 years and <60 years) (n=5338)
Alive at age 55 years (n=12 697)
Attended ≥1 examination at age 50 to <60 years (n=7129)
Eligible with an index examination (n=5606)
Died at age <55 years (n=230)
Excluded (n=1523):
  Prevalent atrial brillation at examination or age ≤55 years (n=73)
  Missing data on risk factors (smoking, alcohol, body mass index, blood pressure,
    diabetes, and history of heart failure or myocardial infarction) during age window
    from 50 to <60 years (n=1450)
Did not attend an examination during age window from 50 to <60 years (n=5568)
No follow-up information aer index examination (n=268)
Fig 1 | Selection of study sample with index age 55 years
Table 2 | Characteristics of participants in three study samples. Data are number (%) of participants unless stated 
otherwise
Characteristic and risk factor
Index age
55 years (n=5338) 65 years (n=4805) 75 years (n=3199)
Male 2531 (47.4) 2126 (44.3) 1291 (40.4)
Age (years; mean (standard deviation)) 55 (1) 65 (1) 75 (1)
Calendar year for Framingham Heart Study examination 
(median (interquartile range)
1995 (1985-2005) 1993 (1982-2005) 1992 (1983-2001)
Length of follow-up (years; median (interquartile range)) 14 (7-22) 11 (6-18) 8 (4-13)
Smoking
 Optimal 1935 (36.3) 1570 (32.7) 1233 (38.5)
 Borderline 2275 (42.6) 2414 (50.2) 1667 (52.1)
 Elevated 1128 (21.1) 821 (17.1) 299 (9.4)
Alcohol
 Optimal 4283 (80.2) 3857 (80.3) 2767 (86.5)
 Elevated 1055 (19.8) 948 (19.7) 432 (13.5)
Body mass index
 Optimal 1785 (33.4) 1537 (32.0) 1126 (35.2)
 Borderline 2136 (40.0) 2008 (41.8) 1364 (42.6)
 Elevated 1417 (26.6) 1260 (26.2) 709 (22.2)
Blood pressure
 Optimal 1539 (28.8) 778 (16.2) 272 (8.5)
 Borderline 1792 (33.6) 1303 (27.1) 676 (21.1)
 Elevated 2007 (37.6) 2724 (56.7) 2252 (70.4)
Diabetes
 Optimal 3805 (71.3) 3137 (65.3) 2249 (70.3)
 Borderline 1187 (22.2) 1149 (23.9) 584 (18.3)
 Elevated 346 (6.5) 519 (10.8) 366 (11.4)
History of heart failure or myocardial infarction
 Optimal 5069 (95.0) 4236 (88.2) 2623 (82.0)
 Elevated 269 (5.0) 569 (11.8) 576 (18.0)
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to 9%. The characteristics of participants divided into 
optimal, borderline, and elevated smoking profiles are 
reported in supplementary table 1.
Single risk factor and lifetime risk of atrial 
fibrillation
The median follow-up time and number of participants 
with first developed atrial fibrillation were 14 years 
(interquartile range 7-22) and 816 for index age 55 
years, respectively. Corresponding values were 11 (6-
18) years and 1023 for index age 65 years, and eight 
(4-13) years and 776 for index age 75 years. The overall 
lifetime risk of atrial fibrillation was 37.0% (95% 
confidence interval 34.3% to 39.6%) for index age 55 
years, 33.7% (31.9% to 35.5%) for index age 65 years, 
and 30.8% (28.9% to 32.7%) for index age 75 years. 
Table 3 reports the lifetime risk of atrial fibrillation 
associated with optimal, borderline, or elevated risk 
factors. The associated lifetime risk of atrial fibrillation 
was lowest if the risk factor profile was optimal. The 
lifetime risk of atrial fibrillation increased gradually 
as the risk factor profile changed from optimal to 
borderline and elevated at each index age. The opposite 
association was seen with a history of smoking; lifetime 
risk of atrial fibrillation was higher among participants 
with optimal (never) and borderline (former) smoking 
than among those with elevated smoking (current 
smoker at index examination).
For example, the lifetime risk of developing atrial 
fibrillation between age 55 and 95 years when blood 
pressure is optimal at age 55 years was 29.0%, after 
accounting for the competing risk of death.
The lifetime risks according to single risk factors 
stratified by sex are in supplementary tables 2-4 for index 
ages 55, 65, and 75 years, respectively. The lifetime risk 
of atrial fibrillation was lower in women than in men.
Multiple risk factors
Supplementary table 5 shows that among participants 
with index age 55 years, 247 (4.6%) had an optimal 
risk profile, 1415 (26.5%) had a borderline risk 
profile, and 3676 (68.9%) had an elevated risk 
profile. The proportion of participants with optimal 
risk factors changed from 4.6% to 2.1% and 1.0%, 
when index age increased from 55 to 65 and 75 years, 
respectively. Accordingly, the proportion with one or 
more borderline risk factors fell as age increased. The 
proportion of participants with at least three elevated 
risk factors increased gradually from 11.1% to 15.8% 
and 14.0% as index age rose from 55 to 65 and 75 
years, respectively.
Multiple elevated or borderline risk factors and 
lifetime risk of atrial fibrillation
Figure 2 and supplementary figures 3 and 4 show the 
lifetime risk of atrial fibrillation for index ages 55, 65, 
and 75 years, respectively, with optimal, borderline, or 
elevated risk factor profiles. The lifetime risk of atrial 
fibrillation was lowest among those with optimal risk 
factors, whereas it was significantly higher in the group 
with elevated risk factors for index age 55 and 65 years 
(table 4). The lifetime risk of atrial fibrillation in each 
risk factor profile was higher among men than among 
women, with a quantitative interaction between sex 
and risk categories because the increase in lifetime risk 
from optimal to borderline risk profiles was larger in 
men than women.
Table 5 and supplementary tables 6 and 7 show the 
lifetime risk of atrial fibrillation among participants 
with multiple borderline or elevated risk factors, 
and the lifetime risk when separated into men only 
and women only, respectively. If all risk factors were 
optimal, the lifetime risk of atrial fibrillation ranged 
Table 3 | Lifetime risk (%) of atrial fibrillation by individual risk factor, after adjustment for competing risk of death
Risk factor  
and category
Index age 55 years Index age 65 years Index age 75 years
No of atrial fibrillation 
cases/total
Lifetime risk  
(95% CI)
No of atrial fibrillation 
cases/total
Lifetime risk  
(95% CI)
No of atrial fibrillation 
cases/total
Lifetime risk  
(95% CI)
Smoking
Optimal 249/1935 38.1 (33.2 to 43.1) 316/1570 33.7 (30.4 to 36.9) 294/1233 30.2 (27.1 to 33.2)
Borderline 343/2275 39.3 (34.9 to 43.6) 525/2414 36.3 (33.6 to 39.1) 410/1667 32.2 (29.4 to 35.0)
Elevated 224/1128 32.1 (28.2 to 36.1) 182/821 27.5 (24.0 to 31.0) 72/299 26.0 (20.6 to 31.3)
Alcohol
Optimal 600/4283 35.1 (32.2 to 38.0) 799/3857 33.2 (31.2 to 35.3) 671/2767 30.8 (28.7 to 32.8)
Elevated 216/1055 40.9 (36.1 to 45.7) 224/948 35.6 (31.6 to 39.5) 105/432 30.7 (25.4 to 36.0)
Body mass index
Optimal 236/1785 31.6 (27.5 to 35.7) 314/1537 29.9 (27.0 to 32.8) 255/1126 27.2 (24.2 to 30.2)
Borderline 343/2136 38.2 (34.0 to 42.4) 422/2008 33.3 (30.5 to 36.1) 319/1364 30.1 (27.2 to 33.0)
Elevated 237/1417 44.2 (38.5 to 50.0) 287/1260 40.7 (36.7 to 44.8) 202/709 38.7 (34.2 to 43.2)
Blood pressure
Optimal 152/1539 29.0 (24.2 to 33.9) 118/778 27.5 (22.9 to 32.1) 45/272 22.4 (16.4 to 28.5)
Borderline 272/1792 36.5 (32.0 to 41.0) 254/1303 30.2 (26.9 to 33.5) 140/675 25.9 (22.1 to 29.8)
Elevated 392/2007 41.1 (37.2 to 44.9) 651/2724 37.1 (34.6 to 39.5) 591/2252 33.1 (30.8 to 35.4)
Diabetes
Optimal 624/3805 36.5 (33.7 to 39.4) 726/3137 32.8 (30.8 to 34.8) 580/2249 30.1 (28.0 to 32.3)
Borderline 128/1187 38.0 (24.6 to 51.5) 171/1149 32.9 (27.0 to 38.7) 110/584 31.7 (25.7 to 37.7)
Elevated 64/346 34.8 (27.3 to 42.4) 126/519 36.5 (30.7 to 42.2) 86/366 32.3 (26.1 to 38.5)
History of heart failure or myocardial infarction
Optimal 747/5069 37.0 (34.3 to 39.8) 864/4236 33.4 (31.4 to 35.3) 607/2623 29.8 (27.7 to 31.9)
Elevated 69/269 37.3 (29.1 to 45.4) 159/569 35.9 (31.2 to 40.7) 169/576 35.1 (30.4 to 39.8)
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from 15.4% to 23.4% across the three study samples. 
By contrast, if at least one risk factor was elevated, 
the lifetime risk of atrial fibrillation was at least 
37.8%.
Predicted lifetime risk of atrial fibrillation
Supplementary table 8 presents the multivariable 
prediction model of the lifetime risk of atrial fibrillation. 
The predicted lifetime risk of atrial fibrillation is 
shown in figure 3 for 16 different risk profiles in men 
and women, separately. We found a higher predicted 
lifetime risk of atrial fibrillation in men than in women. 
Moreover, the presence of hypertension treatment, 
body mass index of 35, elevated alcohol consumption, 
and history of myocardial infarction or heart failure at 
index age 55 years was associated with the greatest 
predicted lifetime risk of atrial fibrillation in both 
men and women. Supplementary figure 5 shows the 
assessment of the calibration and discrimination of the 
prediction model.
Secondary analysis
Supplementary table 9 reports the lifetime risk of atrial 
fibrillation based on a model unadjusted for competing 
risk of death. For all five risk factors, the lifetime risk of 
atrial fibrillation increased gradually from optimal to 
borderline and to elevated, including for smoking and 
diabetes. Similar patterns were seen in all three study 
samples at index ages 55, 65, and 75 years.
Sensitivity analysis
Firstly, we imputed missing data and estimated the 
lifetime risks of atrial fibrillation by multiple risk 
factors (supplementary table 10). Based on the imputed 
data, we found similar lifetime risks to our main results 
(table 4). Secondly, we removed participants with a 
body mass index of less than 18.5 (n=34, 44, and 44 
for index age 55, 65, and 75 years, respectively) from 
the optimal body mass index category (supplementary 
table 11). The lifetime risks of atrial fibrillation 
remained consistent with our results in table 3.
discussion
Principal findings
We used data from three generations of participants 
in the Framingham Heart Study to estimate the 
lifetime risk of atrial fibrillation in various subgroups 
according to the burden of modifiable risk factors. 
Firstly, among participants aged 55 years or older, 
the overall lifetime risk of atrial fibrillation was 
37.0%. Secondly, the lifetime risk of atrial fibrillation 
was higher in men than in women. Thirdly, among 
participants aged 55 years or older and with an 
optimal risk factor profile, the lifetime risk of atrial 
fibrillation was about one in five. Finally, having at 
least one elevated risk factor was associated with 
a lifetime risk of atrial fibrillation of at least one in 
three. Our study shows that the risk factor burden and 
having multiple morbidities have a crucial role in the 
lifetime risk of atrial fibrillation.
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Fig 2 | Cumulative risk (%) for atrial fibrillation according 
to risk factor burden (optimal, borderline, or elevated) at 
index age 55 years. Shading=95% confidence intervals. 
Participants entered the study sample between ages 55 
and <60 years; therefore, the number at risk increased 
from age 55 years to <60 years
Table 4 | Lifetime risk (%) of atrial fibrillation in men and women according to risk factor burden, after adjustment for competing risk of death
Study sample 
(index age) 
 and risk  
category
All Men Women
No of atrial  
fibrillation  
cases/total
Lifetime risk  
(95% CI) P* P†
No of atrial  
fibrillation  
cases/total
Lifetime risk  
(95% CI) P* P†
No of atrial  
fibrillation  
cases/total
Lifetime risk  
(95% CI) P* P†
55 years
Optimal 18/247 23.4 (12.8 to 34.5)
<0.001
— 7/55 29.8 (9.7 to 49.9)
0.01
— 11/192 20.5 (7.3 to 33.7)
0.006
—
Borderline 163/1415 33.4 (27.9 to 38.9) 0.11 94/617 39.7 (31.7 to 47.7) 0.37 69/798 28.0 (20.6 to 35.4) 0.33
Elevated 635/3676 38.4 (35.5 to 41.4) 0.009 388/1859 43.3 (38.4 to 46.2) 0.20 247/1817 34.6 (30.3 to 39.0) 0.05
65 years
Optimal 9/100 18.1 (6.7 to 29.4)
<0.001
— 4/21 28.8 (3.0 to 54.6)
<0.001
— 5/79 14.9 (2.2 to 27.6)
<0.001
—
Borderline 136/921 26.1 (22.0 to 30.1) 0.19 67/359 32.1 (25.3 to 38.9) 0.81 69/562 22.1 (17.2 to 27.0) 0.30
Elevated 878/3784 35.8 (33.8 to 37.9) 0.003 464/1746 39.7 (36.6 to 42.7) 0.41 414/2038 32.7 (30.0 to 35.4) 0.007
75 years
Optimal 4/33 15.4 (1.3 to 29.5)
<0.001
— 1/5 25.0 (0.0 to 67.4)
0.09
— 3/28 13.8 (0.0 to 28.3)
0.003
—
Borderline 87/492 23.6 (19.1 to 28.2) 0.28 42/191 28.3 (20.6 to 36.1) 0.85 45/301 20.6 (15.0 to 26.1) 0.38
Elevated 685/2674 32.2 (30.0 to 34.3) 0.02 315/1095 36.4 (33.0 to 39.9) 0.51 370/1579 29.3 (26.7 to 32.0) 0.03
* Overall test comparing subhazard distributions across risk categories by Fine-Gray method. P<0.001 for interaction between sex and risk categories for index ages 55, 65, and 75 years.
† Test comparing lifetime risk in borderline and elevated risk groups with optimal risk group by z ratio test (that is, difference in lifetime risk between two groups divided by its standard error).
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Comparison with other studies
In 2004, Lloyd-Jones and colleagues reported that men 
and women aged 40 years or older had a lifetime risk of 
atrial fibrillation of one in four.12 The study was based 
on the Framingham Heart Study, with the last follow-up 
in 1999. Our study included more participants in the 
third generation cohort and had an additional 15 years 
of follow-up. In our study, the overall lifetime risk of 
atrial fibrillation ranged from 31% to 37%. The higher 
lifetime risk found in our study could be explained by 
several temporal changes, such as advancing age of 
the population and increased surveillance for atrial 
fibrillation.
Our study is also an extension to the 2004 study,12 
because our current work elaborates on the lifetime 
risk of atrial fibrillation with multiple risk factors. With 
reference to an optimal risk factor profile, we found 
that only an elevated risk factor profile significantly 
increased the lifetime risk of atrial fibrillation, whereas 
a borderline risk factor profile was not associated with 
a significantly increased lifetime risk. Moreover, we 
found that individuals with all optimal risk factors had 
a lifetime risk of atrial fibrillation of about one in five, 
whereas individuals with multimorbidity (defined as 
at least two elevated risk factors) had a lifetime risk 
greater than one in three.
Despite the remarkable increase in lifetime risk 
among individuals with elevated versus optimal risk 
factor burdens, those with an optimal risk factor 
profile still had about a 20% risk of developing 
atrial fibrillation in our study. A meta-analysis of 
18 cohorts showed that among individuals aged 55 
years and with an optimal risk factor profile, the 
lifetime risk of atherosclerotic cardiovascular disease 
was 14.6%.24 Our data suggest that the lifetime risk 
of atrial fibrillation is higher than the lifetime risk of 
atherosclerotic cardiovascular disease if a person has 
an optimal risk factor profile at age 55 years. However, 
future studies comparing lifetime risk of different 
diseases and in different racial and ethnic groups are 
warranted.
We found that both the lifetime risk and predicted 
lifetime risk of atrial fibrillation were higher in men 
than in women, which accords with the results from 
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Fig 3 | Predicted lifetime risk (%) of atrial fibrillation at index age 55 years across 16 risk profiles, in men and 
women. Profiles were defined according to treatment for hypertension (yes or no), body mass index (25 or 35), 
alcohol (elevated (E) or optimal (O)), and history of myocardial infarction or heart failure (yes or no). For each profile, 
participants with an average blood pressure level (mean systolic blood pressure 128 mm Hg and 124 mm Hg and mean 
diastolic blood pressure 80 mm Hg and 76 mm Hg for men and women, respectively), who never smoked, and who had 
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Table 5 | Lifetime risk (%) of atrial fibrillation by risk factor profile and number of elevated/borderline risk factors, after adjustment for competing 
risk of death
Risk factor profile and  
number of elevated/ 
borderline risk factors
Index age
55 years 65 years 75 years
No of atrial  
fibrillation  
cases/ total Lifetime risk (95% CI)
No of atrial 
fibrillation 
cases/ total Lifetime risk (95% CI)
No of atrial  
fibrillation  
cases/ total Lifetime risk (95% CI)
Optimal
0/0 18/247 23.4 (12.8 to 34.5) 9/100 18.1 (6.7 to 29.4) 4/33 15.4 (1.3 to 29.5)
Borderline
0/1 58/520 31.9 (24.5 to 40.3) 44/279 24.9 (18.2 to 31.7) 18/138 18.0 (10.2 to 25.8)
0/2 68/549 38.6 (28.8 to 48.5) 65/377 31.2 (24.6 to 37.9) 40/214 23.8 (17.2 to 30.4)
0/≥3 37/346 27.3 (18.4 to 36.2) 27/265 19.7 (12.4 to 26.9) 29/140 28.9 (19.3 to 38.6)
Elevated
1/any 266/1863 37.8 (33.1 to 42.4) 373/1671 35.7 (32.6 to 38.8) 296/1253 29.2 (26.3 to 32.2)
2/any 225/1220 38.8 (34.0 to 43.5) 313/1355 36.0 (32.6 to 39.4) 268/972 34.9 (31.3 to 38.5)
≥3/any 144/539 39.1 (33.6 to 44.6) 192/758 35.9 (31.6 to 40.2) 121/449 34.4 (29.0 to 39.8)
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a European cohort study.25 In the European study, the 
authors further explored the association between sex 
differences in risk of atrial fibrillation and presence 
of risk factors. They found that women had a more 
favorable risk profile of atrial fibrillation than men—
that is, women smoked less, consumed less alcohol, 
had a lower body mass index and blood pressure, and 
had lower levels of diabetes.25
The Rotterdam Study, a population based prospective 
study in the Netherlands with 6808 participants, also 
investigated the lifetime risk of atrial fibrillation; the 
results were similar to the 2004 study by Lloyd-Jones 
and colleagues.12 13 Although comparable results were 
found in a Swedish study,15 researchers in a Chinese 
study estimated the lifetime risk of atrial fibrillation 
to be one in five at age 55 years.14 Other studies have 
reported that the incidence of atrial fibrillation is lower 
among Asians than European ancestry populations,26 
and the Multi-Ethnic Study of Atherosclerosis from the 
USA reported an incidence of 3.9 in Asians versus 11.2 
in white people per 1000 person years.27 These four 
earlier studies did not take into account the influence 
of the risk factor burden on lifetime risk; but in our 
study, we report that the risk factor burden, comprising 
modifiable risk factors, has a crucial role on the lifetime 
risk of atrial fibrillation. In another study, our group 
has shown that the lifetime risk of atrial fibrillation 
also depends on genetic predisposition.28
Based on 14 598 participants from the 
Atherosclerosis Risk in Communities (ARIC) Study, 
Huxley and colleagues examined the importance of 
individuals being exposed to optimal, borderline, or 
elevated risk factors and the associated risk of incident 
atrial fibrillation over a mean period of 17.1 years.10 The 
risk factor categories were similar to our present study. 
Huxley and colleagues found that a profile of optimal, 
borderline, or elevated risk factors was associated with 
an incidence of atrial fibrillation of 2.19, 3.68, and 
6.59 per 1000 person years, respectively. The results 
from our study also showed a gradual increase in risk of 
atrial fibrillation when having an optimal, borderline, 
or elevated risk factor profile. 
Among the modifiable risk factors included in our 
study, we found that obesity was the most prominent 
risk factor influencing the lifetime risk of atrial 
fibrillation. Another study from the Framingham Heart 
Study reported the temporal changes in risk factors of 
atrial fibrillation over 50 years and found that obesity 
has been a significant risk factor of atrial fibrillation 
in the past five decades.1 The same study showed that 
body mass index was associated with an increasing 
trend in the population attributable fraction of incident 
atrial fibrillation. In the period from 1998 to 2007, the 
population attributable fraction was −2.1 for systolic 
blood pressure, 19.5 for hypertension treatment, 16.9 
for body mass index, no substantial contribution for 
smoking, 5.9 for diabetes, 1.4 for heart failure, and 
3.6 for myocardial infarction.1 The study by Huxley 
and colleagues confirmed that obesity and elevated 
blood pressure had the highest population attributable 
fractions of developing atrial fibrillation (12.7 and 
21.6, respectively).10 In our study, diabetes was not 
associated with the lifetime risk of atrial fibrillation, 
and history of myocardial infarction or heart failure 
had a decreasing role on the lifetime risk of atrial 
fibrillation with greater index age.
For smoking as a risk factor, we observed a 
pattern in which the lifetime risk of atrial fibrillation 
increased from optimal to borderline risk burdens, 
but attenuated from borderline to elevated risk 
burdens. This attenuation in lifetime risk could have 
several explanations. Firstly, in the models that were 
unadjusted for competing risk of death, the lifetime risk 
of atrial fibrillation was highest among participants 
with an elevated smoking profile, suggesting that they 
had a higher risk of death than those with an optimal 
or borderline smoking profile. A plausible explanation 
is that current smokers were more likely to die before 
they developed atrial fibrillation. Atrial fibrillation 
is also an age related disease, with events occurring 
at advanced ages, but most smokers die before they 
reach such advanced ages.1 29 Similarly, Mamun and 
colleagues concluded in an observational study that 
current smokers had a shorter life expectancy than 
never smokers; therefore, current smokers had a 
diminished or the same lifetime risk of cardiovascular 
disease as never smokers.29
Secondly, based on the models adjusted for competing 
risk of death, the results for smoking could have been 
influenced by survivorship bias. One hypothesis is that 
participants who were current smokers at index age 
75 years and survived the following 10 years without 
developing atrial fibrillation could have had a higher 
chance of survival and being free of atrial fibrillation 
than with those who were never smokers or former 
smokers at index age 75 years, because of a low 
predisposition to cardiovascular disease.30 31 Lastly, 
among older people, smokers are more likely to quit 
smoking than never smokers are to initiate smoking; 
smoking cessation during follow-up could have 
neutralized the anticipated high lifetime risk of atrial 
fibrillation among those with an elevated smoking 
profile at index age. The awareness of smoking related 
diseases has increased, supportive actions in smoking 
cessation have progressed, and changes in social policy 
might all have had a temporal effect and enhanced 
smoking cessation during follow-up in our study.32
In the USA, median inpatient expenses related to atrial 
fibrillation per Medicare beneficiary have increased 
substantially, from US$2932 (£2068; €2373) in 1999 
to $4719 in 2013.33 Furthermore, many patients 
with atrial fibrillation may undergo catheter ablation 
procedures, rates of hospital admissions related to 
atrial fibrillation have increased by 1% per year, stroke 
risk in patients with atrial fibrillation have increased 
by a factor of five, and patients with atrial fibrillation 
are at a higher risk of developing other cardiovascular 
diseases.19 33 34 The prevention of atrial fibrillation is 
essential both from the societal health and economic 
perspective, as well as for individual patients burdened 
with atrial fibrillation. Our study indicates that in 
practice, primary prevention of atrial fibrillation could 
RESEARCH
the bmj | BMJ 2018;361:k1453 | doi: 10.1136/bmj.k1453 9
begin with the management of modifiable borderline 
and elevated risk factors, together with reductions 
in multimorbidity. Early intervention and control of 
modifiable risk factors could reduce the number of 
individuals developing atrial fibrillation. Therefore, 
there is the potential for the burden of atrial fibrillation 
to be reduced in addition to the costs associated with 
atrial fibrillation.
Strengths and limitations of study
The first major limitation in our study was related to the 
risk factor exposures. The risk factors examined in our 
study were the most established risk factors for atrial 
fibrillation. However, our study did not include other 
potential risk factors for atrial fibrillation, such as family 
history of atrial fibrillation due to risk of misclassification 
bias or heart murmur, social deprivation, ethnicity, 
or genetic risk profiles owing to missing data.18 28 Our 
study was also not performed with time dependent 
updates of the risk factor profiles during follow-up.35 In 
the borderline and elevated risk categories for smoking, 
we did not take into account the number of pack years 
and the time since a participant had discontinued 
smoking in the borderline group. Moreover, the 
definition of optimal, borderline, and elevated blood 
pressure varies between different countries and has 
changed with recent guidelines, which could affect the 
generalizability.36 Furthermore, some participants had 
multiple overlapping risk factors, but in the current 
analyses we were not able to take into account the 
diverse weights of multiple risk factors on lifetime risk 
of atrial fibrillation. We also used univariate lifetime 
risk models, and had limited statistical power in some 
of our analyses, in particular at advanced index age in 
the participant group with optimal risk factor profiles. 
The limited statistical power might have weakened the 
clinical implications of our results.
The second major limitation was linked to 
outcome. We were not able to distinguish between 
atrial fibrillation subtypes in our study. Moreover, 
some individuals could have had undiagnosed atrial 
fibrillation, resulting in an underestimated lifetime 
risk of atrial fibrillation. In the Framingham Heart 
Study, we cannot rule out surveillance bias. Finally, 
our observational study design limits the ability to 
establish causal pathways, and only associations 
between risk factor profiles and lifetime risk of atrial 
fibrillation can be concluded from our study. The 
Framingham Heart Study is comprised mostly of 
individuals of European ancestry, which limits the 
generalizability to populations from other races or 
ethnicities. Our model to predict the lifetime risk of 
atrial fibrillation was based on only one cohort, with 
moderate discriminative ability, and the prediction 
model will need validation in other cohorts.
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